SANTA ROSA, Calif., Sept. 11, 2012 /PRNewswire/ -- Osseon announces the release of Osseoflex® SN+(steerable needle) for the treatment of vertebral compression fractures (VCF). Osseoflex SN+ is the latest addition to Osseon's family of vertebral augmentation medical devices.Osseoflex SN+ is steerable and can be used for either bipedicular or unipedicular access, cavity creation, and vertebral augmentation within the vertebral body.
Osseoflex SN+ shares all of the features and benefits of the previously released Osseoflex® SN, with the addition of a larger gauge and a stiffer needle for cement delivery during treatment of compression fractures in the vertebral spine.
"Both the Osseoflex SN+ and the Osseoflex SN steerable needles provide patients and physicians with unprecedented treatment options. They are the only VCF cavity creation devices that allow for bipedicular straight access, bipedicular directional access, and unipedicular directional access to the vertebral body," stated John Stalcup, Osseon's President.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.
For more information, visit our website at osseon.com.
Osseon is a registered trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
SOURCE Osseon Therapeutics, Inc.